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Abstract 
Background: The noble gas helium induces pre- and postconditioning in animals and humans. Volatile anesthetics 
induce cardioprotection in humans undergoing coronary artery bypass graft (CABG) surgery. We hypothesized that 
helium induces pre- and postconditioning in CABG-patients, affecting signaling molecules protein kinase C-epsilon 
(PKC-ε), p38 mitogen activated protein kinase (p38 MAPK), extracellular signal-regulated kinase 1/2 (ERK-1/2) and heat 
shock protein 27 (HSP-27) within cardiac tissue, and reducing postoperative troponin levels.
Methods: After ethical approval and informed consent, 125 elective patients undergoing CABG surgery were 
randomised into this prospective, placebo controlled, investigator blinded, parallel arm single-centre study. Helium 
preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postcondi-
tioning (15 min of helium) was applied before release of the aortic cross clamp. Signaling molecules were measured 
in right atrial appendix specimens. Troponin-T was measured at 4, 12, 24 and 48 h postoperatively.
Results: Baseline characteristics of all groups were similar. Helium preconditioning did not significantly alter the 
primary outcome (molecular levels of kinases PKC-ε and HSP-27, ratio of activated p38 MAPK or ERK ½). Postoperative 
troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically sig-
nificant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 
11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), 
p = 0.13]. No adverse effects related to study treatment were observed in this study.
Conclusions: No effect was observed of helium preconditioning, postconditioning or the combination thereof on 
activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-ε in the human heart. Helium pre- and postconditioning 
did not affect postoperative troponin release in patients undergoing CABG surgery.
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Background
Noble gases like xenon can induce cardioprotection via 
preconditioning [1–6]. The signal transduction cas-
cade mediating this effect has partly been described and 
shares similarities with transduction cascade mediating 
ischemic preconditioning [7, 8]. This noble gas induced 
cardioprotective effect was abolished on a cellular level 
by blockers of protein kinase C (PKC) and p38 mitogen 
activated protein kinase (p38 MAPK) [3]. Xenon pre-
conditioning also involves extracellular-signal-regulated 
kinases-1 and -2 (ERK1/2) [6], leading to intracellular 
translocation of heat shock protein 27 (HSP-27) [4].
The non-anesthetic noble gas helium has no relevant 
cardiopulmonary side effects and is already clinically 
used in patients with airway diseases [9, 10]. It can easily 
and safely be administered using readily available venti-
lators and in critical care patients [11, 12]. Experimental 
data from different laboratories in different animal spe-
cies have demonstrated profound protective effects of 
helium against ischemia–reperfusion damage of the heart 
[1, 13, 14]. In a previous study in healthy volunteers, we 
demonstrated that 3 times 5 min of 79 % helium inhala-
tion prevented post-ischemic endothelial dysfunction 
[15]. Experimental data indicated involvement of simi-
lar signal cascades during helium conditioning as were 
shown before for xenon and anesthetic induced condi-
tioning [1]. However, the exact underlying mechanism of 
helium protection in humans remains unclear.
Different preconditioning protocols are currently used 
to induce anesthetic preconditioning, either via con-
tinuous administration throughout surgery [16], during 
ischemia/reperfusion [17] or before aortic cross clamping 
[18]. It is known that both, timing and repetition of the 
preconditioning stimulus, are central for producing the 
respective protection.
Based on the experimental and first clinical data 
on helium conditioning we hypothesized that helium 
induces pre- and/or postconditioning in human myocar-
dium of patients undergoing CABG surgery, involving 
regulation of PKC, p38 MAPK, ERK 1/2 and HSP-27, and 
reducing postoperative troponin T release.
Methods
The institutional review board of the Academic Medical 
Center, Amsterdam, The Netherlands, approved the trial 
registered in the Dutch trial register (number NTR1226). 
Inclusion into this prospective, placebo controlled, inves-
tigator blinded, parallel arm single-center study took 
place from 8/7/2008 to 3/7/2011 at the Academic Medi-
cal Center, Amsterdam, The Netherlands, in accordance 
with the International Conference on Harmonization on 
Good Clinical Practice Guidelines and the Declaration of 
Helsinki. Patients were randomized to one of five paral-
lel groups in a 1:1:1:1:1 allocation ratio using web-based 
randomization software (ALEA; NKI; Amsterdam, The 
Netherlands) with a fixed block scheme, a block size of 
5 patients and stratification on sex (see Fig. 1). While the 
anesthesiologist and the investigator in the operating 
room were not blinded, the patients as well as the inves-
tigators performing laboratory data analysis (troponin T 
values, Western Blot experiments) were blinded to the 
randomization strategy. Patients were recruited by self-
selecting, and all subjects gave written informed consent. 
Exclusion criteria were age <18  years, legal incapacity, 
emergency operations, combined coronary artery and 
heart valve procedures, off-pump procedures, diabetes 
mellitus, severe chronic obstructive pulmonary disease 
(COPD), and left ventricular ejection fraction <30 %. The 
last two criteria were added after publication on http://
www.trialregister.nl but before start of the study.
Fig. 1 Protocol outline. Schematic timeline of the study protocol. 
The black arrows represent the time points at which atrial myocardial 
biopsies were taken. Aox: aortic cross clamp. CPB: cardiopulmonary 
bypass. a Helium preconditioning group. Helium was administered 
in three cycles for 5 min, followed by 5 min inhalation of oxygen 
enriched air (30 % oxygen). b Helium postconditioning group, helium 
administration started at the end of aortic cross clamping for 15 min 
and was continued for 5 min after begin of reperfusion. c Helium 
pre-and postconditioning group. Helium was administered both 
as preconditioning stimulus before cardiopulmonary bypass and 
as postconditioning stimulus at the end of aortic cross clamping. d 
Anesthetic preconditioning group in which sevoflurane was adminis-
tered in three cycles of 5 min. e Untreated controls
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Study protocol
At least two cycles inhalation of sevoflurane were necessary 
to induce preconditioning in humans [18, 19]. We wanted 
to extend the preconditioning stimulus and decided to 
use three cycles of conditioning, as this protocol was also 
used in most experimental studies [20]. The first group 
received helium preconditioning (He-Pre) by inhalation of 
three cycles of helium for 5 min, followed by 5 min inha-
lation of oxygen-enriched air (30  % oxygen). Helium was 
obtained as a mixture with oxygen (Heliox: 79  % helium 
and 21  % oxygen, BOC, Mordon, United Kingdom) and 
administered using a non-invasive helium delivery system 
(Helontix Vent, Linde Therapeutics, Eindhoven, The Neth-
erlands) modified to allow manual ventilation in a Maple-
sons A configuration. All patients were ventilated the same 
way by the same investigator. Extra oxygen was added and 
the final concentration of the gas-mixture was 70 % helium 
and 30 % oxygen. He-Pre was administered shortly before 
start of cardiopulmonary bypass (CPB). A graphical pres-
entation of our study protocol is represented in Fig. 1. The 
postconditioning group (He-Post) received at least 15 min 
of helium at the end of aortic cross-clamping, lasting up to 
5 min after release of the clamp. The third group received 
helium as pre- and postconditioning stimulus (He-PP). 
Patients receiving helium pre- and postconditioning thus 
received two conditioning stimuli of helium with dou-
ble time of helium ventilation. To compare the effects of 
helium with the known effects of anesthetic precondition-
ing (APC), the fourth group received three cycles of 5 min 
sevoflurane inhalation with a minimal alveolar concentra-
tion (MAC) of 1.0 MAC, and the auto-flow function of the 
anesthesia machine (Zeus, Dräger Medical, Lübeck, Ger-
many) was used to ensure rapid wash in and wash out of 
sevoflurane. The 5th group was an untreated control group.
Anesthesia
Patients received premedication with temazepam 10 mg 
per os. Induction of anesthesia was performed with intra-
venous administration of midazolam 0.1–0.2  mg  kg−1 
and target controlled infusion of propofol (dosage was 
1–2 mg/kg for induction), sufentanil 1.0–1.5 μg kg−1, and 
rocuronium 0.6  mg  kg−1 for muscle relaxation. Target 
controlled infusion of propofol was continued to main-
tain anesthesia in combination with either continuously 
or intermittently sufentanil.
Surgery
All patients received routine monitoring during opera-
tion and routine surgical techniques were used. A pul-
monary artery catheter was used for cardiac output 
monitoring. The left internal mammary artery was used 
to graft the left anterior descending artery. As additional 
grafts, harvested veins from the leg, the right internal 
mammary artery or one of the radial arteries were used. 
Both, cold crystalloid and cold blood cardioplegia were 
administered antegrade via the aortic root, and manage-
ment of the cardiopulmonary bypass (CPB) was accord-
ing to standard procedure.
Median sternotomy was performed, followed by peri-
cardiotomy after which the first sample of the right atrial 
appendage was obtained. Then the left internal thoracic 
artery was prepared, during which time systemic hep-
arinization was started (300 IU/kg goal: coagulation time 
>450 s). After venous and arterial cannulas for CPB were 
inserted and secured, the second sample of the right 
atrium was obtained which was directly after precondi-
tioning in the applicable groups. Then CPB was started, 
and the aorta was cross-clamped and cardioplegia solu-
tion was infused. All distal anastomoses were performed 
during aortic cross-clamping. Additional cardioplegic 
solution was administered at intervals to maintain a flat 
electrocardiogram. Fifteen minutes before expected 
release of the aortic cross clamp, we started helium post-
conditioning in the designated groups, and continued 
helium ventilation until 5 min after the start of reperfu-
sion. After completion of coronary artery bypass graft-
ing, CPB was discontinued and the third sample of the 
right atrium was obtained. After surgery, patients were 
transferred to the intensive care unit (ICU), received rou-
tine therapy and were weaned from the ventilator. ICU 
and ward staffs were blinded to the treatment allocation.
Blood sampling and tissue preparation
Blood samples were taken before cardiopulmonary 
bypass, 10 min after cardiopulmonary bypass and at the 
end of operation, as well as at 4, 12, 24 and 48  h after 
cardiopulmonary bypass. We measured troponin-T, cre-
atinine kinase and its myocardial specific isoform Cre-
atine Kinase-Muscle/Brain as markers of cellular injury. 
All samples were analysed in the Laboratory of Clinical 
Chemistry of the Academic Medical Centre, Amsterdam, 
The Netherlands.
Atrial samples were immediately flash frozen in liq-
uid nitrogen and stored at −80 ◦C until further process-
ing. Tissue fractionation was performed as described by 
Weber et  al. [6]. Cytosolic, membrane, and the particu-
late fraction were immunoblotted using the Criterion 
Western Blotting system (Biorad, Hercules, CA).
After protein determination by the Lowry method, 
samples were thawed and diluted 1:5 with Sample Buffer 
5 times containing Tris–HCl, glycerol and bromophe-
nol blue. Samples were vortexed and boiled at 95  °C 
before being subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis using Criterion™ 
XT precast gels (Biorad, Hercules, CA). The proteins 
were separated by electrophoresis and transferred to a 
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polyvinylidenfluorid membrane by tank blotting (Volt-
age 200  V for 50–55  min). Non-specific binding of the 
antibody was blocked by incubation with 5  % fat dry 
milk powder or bovine serum albumin solution in tris-
buffered saline containing tween (TBS-T) for 2  h. Sub-
sequently, the membrane was incubated overnight at 
4  °C with the respective primary antibody at indicated 
concentrations. After washing in fresh, cold TBS-T, 
the blot was subjected to the appropriate horseradish 
peroxidase-conjugated secondary antibody for 2  h at 
room temperature. Immunoreactive bands were seen by 
chemiluminescence detected on X-ray film (Hyperfilm 
ECL, Amersham) using the enhanced chemilumines-
cence system Santa Cruz. The blots were quantified using 
a Kodak Image station® (Eastman Kodak Co., Rochester, 
NY, USA) and the results are presented as the ratio of 
phosphorylated to total protein. Values are expressed as 
x-fold average light intensity (AVI) compared with con-
trol. Equal loading of protein on the gel was additionally 
confirmed by detection of actin/α-tubulin and Coomas-
sie staining of the gels.
Antibodies
We used anti-phospho PKC-ε, antibody (1:10.000) and 
total PKC-ε, both from Upstate (Lake Placid, NY). Phos-
pho-ERK1/2 (1:10.000), total ERK 1/2 (1:10.000), Phos-
pho p38 MAPK (1:5.000) and total p38 MAPK (1:5.000) 
were obtained from Cell Signalling (Danvers, MA), HSP 
27 (1:5.000) from Abcam (Cambridge, UK). Both actin 
(1:10.000) and α-tubulin (1:40.000) were obtained from 
Sigma (St. Louis, MO). Peroxidase-conjugated goat anti-
rabbit and donkey anti-mouse antibodies were from 
Jackson Immunoresearch (Suffolk, UK). The enhanced 
chemiluminescence protein detection kit was purchased 
from Santa Cruz (Heidelberg, Germany).
Endpoints and data collection
Primary endpoints of this study are phosphorylation of 
ERK1/2, p38MAPK and expression of HSP27 and PKC-ε 
in the particulate fraction. Secondary endpoints include 
post-operative troponin T release.
Data were collected on age, sex, race, length and 
weight, co-morbidities and risk factors for cardiovascular 
disease, Euroscore, medication usage, duration of bypass, 
and aortic clamping, number and type of grafts. Because 
of technical difficulties establishing reproducible results 
for the western blot we lost n = 5 patients per group for 
these targets (p38 MAPK, ERK1/2, HSP27 and PKC-ε).
Sample size calculation and statistics
Regarding our primary endpoint, no data on the effect 
of noble gas preconditioning on protein expression in 
human myocardial tissue was available while setting up 
the study. A proper sample size calculation was therefore 
not possible at start of the study. However, based on pre-
vious experimental research and a similar clinical study 
[19], we expected to find any—also clinically relevant dif-
ferences—with a sample size of 25 patients per group.
Numerical data are presented as mean ± SD or median 
with interquartile range, as appropriate. Categorical data 
are presented as numbers and percentages. Statistical 
analyses were done using SPSS version 22 (IBM, Armonk, 
New York, USA).
We considered a p value of <0.05 to be statistically sig-
nificant. Statistical testing of the western blot data was 
done using Shapiro–Wilk test for normality and Fried-
mann test for non-parametric data followed by Bonfer-
roni correction for multiple testing (GraphPad Prism 
version 5.0, GraphPad, La Jolla, CA). We chose to graphi-
cally represent our data as mean + SD, however detailed 
information regarding the mean differences of the time-
points from our primary endpoints is available in Addi-
tional file 1.
To compare post-operative troponin T release the area-
under-the-curve was calculated (mentioned as arbitrary 
units) and compared in a one-way-ANOVA.
Results
Baseline characteristics
Four patients were excluded from the study (no helium 
available (1), no investigational team available (1), 
unplanned additional valve surgery (1), previously 
unknown decreased left ventricular ejection fraction 
<30  % (1)), leaving data from 121 patients available for 
statistical analysis (CONSORT diagram see Fig. 2). Base-
line characteristics of all groups were similar with regard 
to age (66 ± 9) and sex (83 % male, Table 1). Preoperative 
demographic data showed that in controls, less patients 
with hypercholesterolemia, or who used statins or beta-
blockers were present compared to the other groups. The 
predictive additive risk determined by Euroscore was 
similar in all groups. The number of bypass grafts and 
duration of aortic cross clamping and CPB duration were 
also similar in all groups (Table 2).
Pre‑ and postconditioning protocols
Helium and sevoflurane pre- and/or postconditioning 
was administered without any problems during surgery. 
Neither the preconditioning nor the postconditioning 
stimulus altered hemodynamics, and no differences in 
heart rate, mean arterial pressure, cardiac index or pul-
monary artery pressure were observed between groups 
(Table  3). We did not measure myocardial oxygen sup-
ply directly, but no differences were observed between 
groups regarding arterial oxygen tension and hemoglobin 
levels (see Additional file 2).
Page 5 of 13Smit et al. J Transl Med  (2016) 14:294 
Phosphorylation of p38 MAPK in cytosolic fraction
We determined in the cytosolic fraction of the myocardial 
atrial tissue the phosphorylated-to-total (p/t) p38 MAPK 
ratios within three biopsies from each patient taken at 
time points described in Fig. 3. In controls, no statistically 
significant changes were observed at begin of CPB and 
after CPB compared to baseline (Fig. 3). In groups receiv-
ing a preconditioning stimulus (He-Pre, He-PP, APC), 
no effect of the preconditioning stimulus on the ratio of 
p/t p38 MAPK was observed (biopsy 2 vs. biopsy 1). In 
addition, also postconditioning (He-Post, He-PP) did not 
affect the ratio p/t p38 MAPK (biopsy 3 vs. biopsy 1).
Phosphorylation of ERK‑1 and ERK‑2 in cytosolic fraction
The ratio of activated (phosphorylated to total, p/t) 
ERK-1 of the cytosolic fraction was determined. In the 
preconditioning groups (He-Pre, APC), a statistically sig-
nificant increase of ratio p/t ERK-1 was observed after 
the preconditioning stimulus (biopsy 2 vs. biopsy 1; Fig. 4 
upper panel). While these changes were still evident after 
CPB in the APC group, the changes were no longer sig-
nificantly different from baseline at the end of CPB in 
the He-Pre group. Postconditioning with helium had no 
effect on ratio p/t ERK-1.
Regarding the ratio p/t ERK-2, no statistically signifi-
cant changes were observed after either pre- or postcon-
ditioning with helium or sevoflurane, nor in the control 
group (Fig. 4, lower panel).
Protein expression of HSP‑27 in particulate fraction
Total levels of HSP-27 were determined in the particu-
late fraction of myocardial atrial tissue. In controls, we 
observed a statistically significant increase of HSP-27 
immediately before as well as after CPB (biopsy 2 and 
3 vs. biopsy 1, respectively; Fig. 5). The same pattern of 
changes in HSP-27 as observed in the control group was 
seen in all other pre- and postconditioning groups, with 
the only exception that in the He-Pre group no increase 
of HSP-27 after CPB (biopsy 3) was seen.
Expression of PKC‑ε in the particulate fraction
Total PKC-ε was determined in the particulate fraction of 
the atrial tissue. In control patients, we did not observe 
any statistically significant difference of PKC-ε levels 
immediately before or after CPB compared to baseline 
(biopsy 2 and 3 vs. biopsy 1, respectively; Fig. 6). Neither 
preconditioning with helium or sevoflurane (He-Pre, 
He-PP, APC), nor postconditioning with helium (He-PP, 
Patients screened 655
Suitable patients 301
Informed consent 134
Randomised 125
Analysed 121
Diabetes Mellitus 157
Off-pump 78
Other exclusion criteria 119
No informed consent 73
Logistical reasons 61
Another study 33
Protocol violation prior to 
randomisation 3
Change in OR schedule 6
Excluded 4 (He-Pre 2; He-Post 2)
Fig. 2 CONSORT diagram
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He-Post) had any statistically significant effect on levels 
of PKC-ε before or after CPB.
Plasma concentrations of postoperative troponin T
Postoperative troponin T was 11 arbitrary units [5, 
31; area-under-the-curve (interquartile range)] for the 
controls, and no statistically significant changes were 
observed after helium preconditioning [He-Pre: 11 (6, 
18)], helium postconditioning [He-Post: 11 (8, 15)], 
helium pre- and postconditioning [He-PP: 14 (6, 20)] 
and after sevoflurane preconditioning [APC: 12 (8, 24), 
p  =  0.13, one-way ANOVA after log transformation, 
Fig. 7].
Discussion
In the present study, we did not observe any relevant 
differences on a molecular level in the regulation pat-
terns of the signal transduction kinases p38 MAPK, 
ERK-1, ERK-2, or PKC-ε after helium treatment as 
compared to the control group. He preconditioning 
alone (without postconditioning) prevented HSP-27 
increase as observed in all other groups. Helium pre- and 
Table 1 Demographic data
Age and body mass index are presented as mean ± SD; Euroscore is presented as mean (±IQR); other data are numbers and percentage, n (%)
a In the control group significantly less patients with hypercholesterolemia were present
b Use of statins was significantly lower in our control group compared to other groups
c Use of beta-blockers was significantly lower in our control group compared to other groups
He-Pre helium preconditioning; He-Post helium postconditioning; He-PP helium pre- and postconditioning; APC anesthetic preconditioning
Age and Body Mass Index are presented as mean ± SD; Euroscore is presented as mean (±IQR); other data are numbers and percentage, n (%). In the control group 
significantly less patients with hypercholesterolemia were present. b Use of statins was significantly lower in our control group compared to other groups. c Use of 
beta-blockers was significantly lower in our control group compared to other groups
Controls He‑pre He‑post He‑PP APC p  value
N 28 23 22 24 24
Age ± years 66.7 ± 7.0 62.8 ± 11.7 66.2 ± 7.8 66.2 ± 8.3 66.9 ± 7.6 0.47
Male (%) 22 (82) 21 (91) 20 (83) 20 (83) 21 (88) 0.88
Body Mass Index 28.4 ± 3.7 27.3 ± 2.7 26.7 ± 3.8 27.4 ± 3.7 27.7 ± 3.2 0.55
Risk factors
 Hypertension 16 (59) 9 (39) 13 (57) 10 (42) 13 (54) 0.52
 Hypercholesterolemia 6 (22) 11 (48) 10 (44) 5 (21) 14 (58) 0.023a
 Smoking 13 (48) 10 (44) 8 (34) 11 (46) 10 (42) 0.89
 Family 12 (44) 9 (39) 7 (30) 9 (38) 13 (54) 0.56
 Myocardial infarction 7 (26) 10 (44) 8 (36) 10 (42) 8 (33) 0.71
 Cerebrovascular accident 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 0.40
Heart failure
 NYHA I 20 (74) 17 (74) 19 (86) 17 (71) 16 (70) 0.97
 NYHA II 2 (7) 2 (9) 1 (5) 2 (8) 3 (13) 0.97
 NYHA III 5 (19) 4 (17) 2 (9) 4 (17) 4 (17) 0.97
Ejection fraction
 >50 % 21 (81) 16 (73) 12 (57) 16 (67) 19 (90) 0.15
 30–50 % 5 (19) 6 (27) 7 (33) 4 (17) 1 (5) 0.15
Medication
 Salicylate 24 (86) 19 (83) 22 (92) 23 (96) 23 (92) 0.57
 Clopidogrel 9 (32) 9 (39) 12 (50) 9 (38) 4 (16) 0.15
 Statinb 27 (96) 23 (100) 24 (100) 20 (83) 21 (84) 0.04b
 Beta-blockerc 19 (68) 22 (96) 24 (100) 21 (88) 21 (84) 0.008c
 ACE inhibitor 10 (36) 8 (35) 10 (42) 4 (17) 11 (44) 0.30
 AT2 receptor blocker 6 (21) 1 (4) 5 (21) 5 (21) 3 (12) 0.40
 Calcium channel blocker 10 (36) 7 (30) 4 (17) 10 (42) 6 (24) 0.35
 Diuretics 6 (21) 4 (17) 4 (17) 7 (29) 4 (16) 0.77
 Nitrates 10 (36) 9 (39) 7 (29) 12 (50) 13 (52) 0.43
 Euroscore 3 (±2) 2 (±3) 3 (±3) 4 (±3) 1 (±3) 0.36
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postconditioning—alone or in combination—did not 
affect postoperative troponin T release in patients under-
going CABG surgery.
Molecular changes by helium
Mechanisms underlying the protection by volatile anes-
thetics and noble gases have been investigated extensively 
in animal experiments [8, 21, 22]. However, mechanis-
tic data from human studies are scarce. We investigated 
whether helium has any influence on signal transduction 
markers known to play a role in noble gas induced cardio-
protection we demonstrated before [3–5, 7, 23]. Although 
p38 MAPK plays a role in inhalational anesthetic induced 
preconditioning [4], we were unable to demonstrate a role 
for p38 MAPK in preconditioning with either helium or 
sevoflurane in this clinical study: the ratio of phospho-
rylated to total p38 MAPK in the cytosolic fraction of 
the myocardial atrial tissue showed no statistically sig-
nificant differences at various time-points in all groups. 
In contrast, Pouzet et  al. demonstrated an increase of 
p38 MAPK after CPB in controls and sevoflurane treated 
patients undergoing CABG surgery [24]. No statistically 
significant difference in PKC-ε levels after precondition-
ing with helium, sevoflurane or in untreated controls was 
observed, which is in contrast to a previous study show-
ing translocation of PKC-ε to the particulate fraction after 
sevoflurane preconditioning [19].
The ratio of phosphorylated-to-total ERK-1 was 
increased after helium preconditioning compared to the 
baseline value, but this effect was no longer present after 
reperfusion at the end of CPB. In contrast, the increased 
ratio of phosphorylated-to-total ERK-1 after sevoflurane 
preconditioning was still present at the end of CPB. For 
ERK-2, no statistically significant effects were found at 
any time-point in any of the groups. In contrast, Talmor 
et  al. demonstrated in atrial tissue obtained at similar 
time-points during CABG surgery an increase in ERK-
1/2 activity after ischemia and reperfusion [25].
Several studies investigated changes of HSP-27 during 
cardiac surgery, most of them measuring HSP in patient 
Table 2 Surgical specifications
Data are presented as mean ± SD; no significant differences were observed between groups
He-Pre helium preconditioning; He-Post helium postconditioning; He-PP helium pre- and postconditioning; APC anesthetic preconditioning
Controls He‑pre He‑post He‑PP APC p  value
ECC time (min) 88 ± 7 84 ± 6 91 ± 5 100 ± 7 95 ± 6 0.53
Cross-clamp time (min) 59 ± 4 54 ± 4 58 ± 5 67 ± 5 62 ± 4 0.51
Cardioplegia
 Blood (%) 18 (82) 17 (85) 18 (82) 14 (67) 18 (78) 0.36
 Saline (%) 4 (18) 3 (15) 4 (18) 7 (33) 5 (22) 0.36
Number of coronary arteries
 1 1 (4) 1 (5) 0 (0) 2 (8) 1 (4) 0.19
 2 9 (33) 6 (27) 4 (17) 8 (33) 7 (29) 0.19
 3 17 (63) 15 (68) 17 (81) 14 (58) 16 (67) 0.19
 Left main 9 (32) 8 (36) 3 (13) 20 (42) 10 (40) 0.88
Table 3 Hemodynamic data
Data are presented as mean ± SD; no significant differences were observed 
between groups
He-Pre helium preconditioning; He-Post helium postconditioning; He-PP 
helium pre- and postconditioning; APC anesthetic preconditioning; CPB 
cardiopulmonary bypass; PCWP pulmonary capillary wedge pressure
Controls He‑pre He‑post He‑PP APC
Heart rate (beats min−1)
 After sternotomy 56 ± 7 59 ± 8 62 ± 12 60 ± 10 60 ± 13
 After precondi-
tioning
60 ± 11 59 ± 8 59 ± 9 61 ± 11 61 ± 13
 After CPB 72 ± 7 73 ± 10 73 ± 14 71 ± 12 80 ± 15
Mean arterial pressure (mmHg)
 After sternotomy 76 ± 12 74 ± 13 76 ± 14 77 ± 13 80 ± 16
 After precondi-
tioning
66 ± 12 69 ± 13 64 ± 12 67 ± 11 68 ± 13
 After CPB 63 ± 12 64 ± 7 66 ± 11 70 ± 11 70 ± 14
Cardiac Index (L/min/m2)
 After sternotomy 2.1 ± 0.6 2.1 ± 0.6 2.0 ± 0.4 2.1 ± 0.4 2.2 ± 0.5
 After precondi-
tioning
2.0 ± 0.7 2.1 ± 0.5 2.0 ± 0.4 2.3 ± 0.4 2.1 ± 0.5
 After CPB 2.4 ± 0.7 2.7 ± 0.8 2.4 ± 0.4 2.5 ± 0.7 2.1 ± 0.8
Pulmonary artery pressure (mmHg)
 After sternotomy 18 ± 6 16 ± 5 16 ± 5 17 ± 4 20 ± 3
 After precondi-
tioning
18 ± 6 18 ± 6 14 ± 5 17 ± 4 18 ± 5
 After CPB 20 ± 6 18 ± 4 18 ± 4 20 ± 5 20 ± 4
PCWP (mmHg)
 After sternotomy 11 ± 6 10 ± 6 8 ± 6 10 ± 2 8 ± 4
 After precondi-
tioning
4 ± 5 9 ± 6 9 ± 7 9 ± 3 9 ± 5
 After CPB 15 ± 6 11 ± 3 8 ± 3 13 ± 3 10 ± 1
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blood [26–28]. Our data demonstrate that in untreated 
controls the level of HSP-27 in atrial tissue increases sig-
nificantly after reperfusion compared to baseline levels. 
Except for the helium-preconditioning group, this effect 
was seen in all treatment groups, indicating that aortic 
cross clamping and subsequent reperfusion increases the 
levels of HSP-27.
Besides the data on PKC-ε, which were used for 
the power calculation, there were no data available of 
ERK1/2, HSP-27 or p38MAPK in human myocardial tis-
sue after preconditioning at start of the current study. 
Although unlikely, we cannot completely exclude the 
possibility that our study was underpowered to detect a 
difference in ERK1/2, HSP-27 or p38MAPK. A clinically 
relevant outcome parameter to be alternatively used for 
power calculation would have been troponin T values 
during the postoperative course. This parameter was 
used in a previous study with much smaller groups sizes 
(n  =  10) [16], showing a significant difference between 
groups. Therefore, we expected to find any clinical rel-
evant differences of troponin release with the current 
group size of 25 patients per group.
Lack of sevoflurane preconditioning
In the present study we were unable to show protection 
in the suggested positive control, namely sevoflurane pre-
conditioning. Demographic data, duration of CPB and 
aortic cross clamping did not differ compared to recent 
studies showing cardioprotection by sevoflurane [18, 19].
In our previous study [19], all patients received crystal-
loid cardioplegia, while in the current study crystalloid 
as well as blood cardioplegia was allowed. However, the 
distribution of crystalloid and blood cardioplegia was 
not significantly different between groups. Theoreti-
cally, a diminished ischemic burden could have affected 
the power needed to obtain protection. Only two car-
diac surgeons performed all procedures in the previous 
study, while in the current study numerous surgeons 
were involved. Larger than expected variations in biop-
sies, both in size as in composition (percentage of muscle 
and fatty tissue), might also have influenced our molecu-
lar results. More detailed information regarding diffi-
culties we encountered during protein analysis of these 
samples are described in Additional file 3. Whether these 
increased diversities in clinical practices might have 
blunted potential cardioprotective effects of sevoflurane 
preconditioning remains unclear.
Opioid-induced cardioprotection might affect addi-
tional cardioprotection by inhalational agents [29], how-
ever all patients received opioids in a comparable dosage, 
which was also performed in our previous study, and it is 
unlikely that this has significantly influenced the results.
Surprisingly, we did not observe any cardioprotective 
effect as measured by troponin T release (see Fig. 7). The 
Fig. 3 Ratio of activated p38 MAPK. The ratio of activated (phosphorylated to total p/t p38MAPK) at three different time points. The baseline ratio 
p/t p38MAPK is represented by biopsy 1. Biopsy 2 represents the ratio directly after application of the preconditioning stimulus, and the biopsy 3 
is at the end of cardiopulmonary bypass. Values presented in mean ± SD. No significant differences were observed in the ratios of p/t p38MAPK 
at different time points in the controls (white dots), after preconditioning with helium (He-Pre; light blue dots) or sevoflurane (APC; orange dots), or 
after postconditioning (He-Post; grey dots) or the combination of helium pre- and postconditioning (He-PP; dark blue dots, Kruskall Wallis rank sum 
analysis)
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volatile anesthetic sevoflurane is one of the few precon-
ditioning agents that so far was successfully translated 
from experimental studies into clinical practice: sevoflu-
rane reduced postoperative troponin release after CABG 
surgery [17–19]. Several meta-analysis showed that the 
modern volatile anesthetics sevoflurane and desflurane 
were associated with a reduction in mortality after car-
diac surgery when compared with total intravenous 
anesthesia [30, 31]. The original data from the studies 
included in these reviews contain small patient groups, 
and the studies used different conditioning protocols 
and stimuli. Another review, focussing on the precon-
ditioning protocol used [32], mentioned that protection 
could be a side effect of sevoflurane induced alterations 
in myocardial oxygen demand and supply, not necessar-
ily indicating preconditioning. Despite the initial success-
ful translation of anesthetic preconditioning into clinical 
practice, more recent studies show more variable or even 
contradictory results. For a definitive answer on whether 
sevoflurane induces preconditioning and which modality 
Fig. 4 Ratio of activated ERK-1 and ERK-2. Ratio of activated (phosphorylated to total, p/t) Extracellular-signal regulated kinases-1 and -2 at different 
time points. a ERK-1 (p44) and b ERK-2 (p42). X axis presents ratio of p/t ERK-1 or -2, Y axis represents different biopsies (1–3) for each group (see also 
legend Fig. 3). Values presented in mean ± SD. For ERK-1, we observed a significant increase in p/t ratio in the helium-preconditioning group in the 
second biopsy (taken after preconditioning) compared to baseline. In the anaesthetic preconditioning group, we observed a significant increase 
compared to controls for biopsy 2 and 3. No significant differences in the ratio of p/t ERK-2 were observed at the different time points
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of its application is most effective, larger randomised 
controlled trials are needed to provide more robust 
evidence.
Lack of helium pre‑ and postconditioning
While the stimulus for preconditioning is applied before 
myocardial ischemia, postconditioning is the protection 
induced by a stimulus applied during ischemia or at the 
beginning of reperfusion. Presence of the stimulus during 
reperfusion seems to be essential for its success to evoke 
protection. Ischemic postconditioning decreased postop-
erative troponin release after cardiac surgery in children, 
[33] and decreased postoperative CK-MB but not tro-
ponin I release in adults [34].
Fig. 5 Levels of HSP-27. Amount of heat shock protein (HSP)-27 (mean ± SD) of the particulate fraction at different time points; X axis is net inten-
sity of the signal of HSP-27. Y axis represents different biopsies (1–3) for each group (see also legend Fig. 3). Except for the helium-preconditioning 
group, a significant increase of total HSP-27 at the end of cardiopulmonary bypass (biopsy 3) compared to the respective baseline values was found. 
For the controls, helium pre- and postconditioning group and the anesthetic preconditioning group this increase was also significant directly after 
preconditioning (biopsy 2) compared to baseline
Fig. 6 Levels of PKC-ε in particulate fraction. Levels of protein kinase C-ε (PKC-ε) in particulate fraction of myocardial atrial tissue at different time 
points (mean ± SD, see also legend Fig. 3). No differences of PKC-ε were observed at different time points in controls, after preconditioning with 
helium (He-pre) of sevoflurane (APC) or after helium postconditioning (He-post) or the combination of helium pre-and postconditioning (He-PP)
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Helium induces protection by postconditioning [13], 
but the current results do not show a beneficial effect of 
helium postconditioning. We started helium postcondi-
tioning at the end of aortic cross clamping by manual ven-
tilation of the lungs—while the patient was still on CPB. 
We did not measure coronary artery (collateral) flow, nor 
did we measure helium concentration in coronary blood. 
We therefore cannot confirm that sufficient helium was 
present within the coronary artery system at the begin-
ning of cardiac reperfusion, and it is possible the postcon-
ditioning stimulus was insufficient. We used 70 % helium, 
allowing an inspiratory concentration of oxygen of 30  %. 
Although experimental data indicate a concentration of 
30–70 % helium to be enough to induce preconditioning 
[14], it cannot be excluded that 70 % helium was too low 
to induce protection in CABG patients with increased age 
and multiple comorbid conditions. We previously showed 
helium induced preconditioning was abolished in aged 
[35] as well as in hypertensive animals [36]. However, in 
the hypertensive rat, a combination of helium induced pre- 
and postconditioning was able to overcome the barrier for 
cardioprotection, leading to reduction of infarct size [36]. 
In our current study, thirteen patients (57  %) from the 
He-PP group had hypertension. However, even the combi-
nation of helium pre- and postconditioning did not result 
in reduction of troponin release in this patient group.
It could be that the general trauma for CABG has 
reduced over time and therefore it will become more and 
more difficult for a protecting agent to show an addi-
tional benefit. Most likely, the most “healthy” CABG 
patients will not profit from additional protection, and 
the possible protective effects of helium in high-risk car-
diac surgery patients (e.g., valve-plus-CABG surgery, 
thoracic aortic surgery) are still unknown.
Conclusion
In patients subjected to on-pump CABG surgery, we 
could not observe any statistically significant effect of 
helium on enzymes of the signal transduction cascade 
of pre- and postconditioning in human atrial tissue, or 
on troponin T release. The use of helium as a cardiopro-
tective agent is still a matter of debate between different 
Fig. 7 Postoperative troponin T levels. The course of postoperative troponin T release; all groups compared to controls (represented in black in 
all panels). Helium preconditioning (He-pre) does not affect postoperative troponin T levels compared to controls (a), nor does helium postcon-
ditioning (He-post, b) or the combination of helium pre- and postconditioning (He-PP, c). Anesthetic preconditioning (APC) with sevoflurane did 
also not affect postoperative troponin T levels compared to controls in the present study (d). X axis represents troponin T level in μg/L, values in 
median ± interquartile range. Y axis represents time (hours)
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study groups; however, this is not the case with sevoflu-
rane, which was also without activity in the current study, 
but brings into question the robustness and true trans-
lational value of this type of cardioprotection in CABG 
surgery.
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